US Penny Stocks to Watch in September 2025: Top 10 Picks with Market Cap and Financial Health Ratings

The article highlights the top 10 penny stocks in the US, including Dingdong (DDL), Waterdrop (WDH), and Puma Biotechnology (PBYI). It also spotlights two of the companies, Zura Bio and Allogene Therapeutics, which have a market cap of $156.69 million and $1.11 billion, respectively. Both companies are debt-free and have sufficient cash runway, but face challenges such as high volatility and negative return on equity. The management teams of both companies are relatively new but experienced, which may aid in navigating these financial hurdles.

As U.S. stock indexes continue to experience fluctuations, investors remain keen on exploring potential growth opportunities in the penny stock market. Penny stocks, characterized by their small market capitalization and relative newness, offer a mix of affordability and growth potential when supported by strong financials. This article highlights the top 10 penny stocks in the U.S., including Dingdong (DDL), Waterdrop (WDH), and Puma Biotechnology (PBYI), and provides insights into two notable companies: Zura Bio and Allogene Therapeutics.

# Top 10 Penny Stocks in the U.S.

| Name | Share Price | Market Cap | Rewards & Risks |
|------------------|-------------|------------|-----------------|
| Dingdong (Cayman) | $2.09 | $435.04M | ✅ 4 ⚠️ 0 |
| Waterdrop (WDH) | $1.95 | $694.39M | ✅ 4 ⚠️ 0 |
| WM Technology (MAPS) | $1.22 | $206.93M | ✅ 4 ⚠️ 2 |
| Puma Biotechnology (PBYI) | $4.72 | $237.25M | ✅ 3 ⚠️ 2 |
| Sensus Healthcare (SRTS) | $3.16 | $51.95M | ✅ 4 ⚠️ 2 |
| Performance Shipping (PSHG) | $2.05 | $23.25M | ✅ 4 ⚠️ 2 |
| Golden Growers Cooperative (GGRO.U) | $5.00 | $77.45M | ✅ 2 ⚠️ 5 |
| Table Trac (TBTC) | $4.70 | $20.88M | ✅ 2 ⚠️ 2 |
| BAB (BABB) | $1.00 | $7.09M | ✅ 2 ⚠️ 3 |
| Lifetime Brands (LCUT) | $3.84 | $86.32M | ✅ 3 ⚠️ 2 |

# Spotlight on Zura Bio and Allogene Therapeutics

Zura Bio
Zura Bio, with a market cap of $156.69 million, is a clinical-stage biopharmaceutical company focused on developing oral therapies for autoimmune, inflammatory, and neurodegenerative diseases. The company, currently pre-revenue, has no debt and sufficient cash to cover both short- and long-term liabilities. However, it faces challenges such as high volatility and negative returns on equity. The management team, although relatively new, is experienced, which may help navigate these financial hurdles.

Allogene Therapeutics
Allogene Therapeutics, with a market cap of $1.11 billion, is a biotechnology company focused on developing allogeneic cell therapies for immune-mediated diseases. The company is debt-free and has sufficient cash to sustain operations. Despite being pre-revenue and experiencing increasing losses, Allogene Therapeutics has a strong management team with an average tenure of 4.4 years, which may aid in overcoming financial challenges.

# Conclusion

Penny stocks, while offering significant growth potential, come with inherent risks. Investors should carefully evaluate the financial health and operational capabilities of these companies before making investment decisions. The top 10 penny stocks in the U.S. provide a mix of opportunities and risks, with companies like Zura Bio and Allogene Therapeutics showcasing promising potential despite facing financial challenges.

References
3 Promising Penny Stocks With Market Caps Under $700M^[1] https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-howl/werewolf-therapeutics/news/3-promising-penny-stocks-with-market-caps-under-700m-1
3 Penny Stocks With Market Caps Over $100M And ...^[2] https://simplywall.st/stocks/us/healthcare/nasdaq-soph/sophia-genetics/news/3-penny-stocks-with-market-caps-over-100m-and-promising-grow